

A multi-faceted intervention to improve syphilis screening and management in pregnant women in Indonesia: the DUALIS (Dual) study

Submission date 27/05/2025	Recruitment status Not yet recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/06/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 30/06/2025	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Mother-to-child transmission (MTCT) of syphilis, also called syphilis is the second leading cause of preventable stillbirths, second only to malaria. In pregnancy, syphilis increases the risk of problems like premature birth, brain damage, nerve damage and bone deformities in the baby. Mother-to-child transmission of syphilis (congenital syphilis) can be prevented by testing pregnant women early in pregnancy and giving treatment promptly if they test positive. Indonesia is reported to have the highest rate of syphilis among pregnant women. Between 2013 and 2023, the level of testing for syphilis among pregnant women rose from <1% to 37% with a positivity rate of 0.48%. Unfortunately, cases of congenital syphilis are on the rise because only 44% of women who currently test positive for syphilis receive treatment due to several challenges related to the health system. Our team will work with the Indonesian government and a leading implementing partner to adapt and evaluate a multifaceted intervention that will focus on improving how syphilis testing and treatment are offered during pregnancy in two provinces of Indonesia.

Who can participate?

Government primary health centres (Puskesmas) and their network of community and private midwives in Central Java and East Nusa Tenggara provinces in Indonesia will participate in the study.

What does the study involve?

We will design a multifaceted intervention to address barriers to screening and treatment for syphilis in pregnancy, evaluate the effectiveness of the intervention compared to current practice, evaluate the uptake and implementation of the intervention, and determine its cost-effectiveness.

What are the possible benefits and risks of participating?

Participating healthcare facility staff will receive training in effectively managing syphilis in pregnant women.

Pregnant women who are positive for syphilis who receive inadequate treatment and their

unborn babies, may benefit by receiving appropriate care when the research team notifies the healthcare staff through monthly reports.

Further, we hope that if our intervention is successful, more pregnant women will be screened, and if testing positive, then receive appropriate treatment, which will lead to improved health outcomes for women and newborns.

We do not expect any additional risks to study participants outside those associated with usual clinical care for patients, or with the usual work routine for health care staff. However, for the study evaluation interviews, discomfort, embarrassment or distress related to discussions about sexually transmitted infections could potentially occur.

Pregnant women may experience decreased mental health if their syphilis status is inadvertently disclosed because of the stigma associated with syphilis.

Where is the study run from?

This is a collaboration between Universitas Gadjah Mada, the London School of Hygiene and Tropical Medicine, United Kingdom (UK), and the Kirby Institute University of New South Wales, Australia.

When is the study starting and how long is it expected to run for?

August 2024 to September 2027

Who is funding the study?

Medical Research Council, UK.

Who is the main contact?

Christa Dewi: christa_dw@yahoo.com

Swasti Sempulur: swasti274@gmail.com

Contact information

Type(s)

Scientific, Principal Investigator

Contact name

Prof Shunmay Yeung

ORCID ID

<https://orcid.org/0000-0002-0997-0850>

Contact details

London School of Hygiene and Tropical Medicine (LSHTM)

Keppel Street

London

United Kingdom

WC1E 7HT

+44 (0) 2079 272657

shunmay.yeung@lshtm.ac.uk

Type(s)

Scientific, Principal Investigator

Contact name

Prof Virginia Wiseman

ORCID ID

<https://orcid.org/0000-0002-7911-0741>

Contact details

The Kirby Institute, University of New South Wales (UNSW)
Sydney
Australia
NSW 2052
+61 (2) 9385 9998
virginia.wiseman@lshtm.ac.uk

Type(s)

Public, Scientific, Principal Investigator

Contact name

Prof Ari Probandari

ORCID ID

<https://orcid.org/0000-0003-3171-5271>

Contact details

Center for Tropical Medicine, Universitas Gadjah Mada
Gedung Penelitian dan Pengembangan FKMK UGM
Jl. Medika, Sendowo, Sinduadi, Kec. Mlati, Kab Sleman
Yogyakarta
Indonesia
55281
+62 274 547147
ari.probandari@staff.uns.ac.id

Additional identifiers**EudraCT/CTIS number**

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

Nil known

Study information**Scientific Title**

A multi-faceted intervention to improve syphilis screening and management in pregnant women in Indonesia: the DUALIS (Dual) study

Study objectives

A multi-faceted intervention to address operational and capacity barriers will accelerate scale-up of antenatal testing and treatment for syphilis in two provinces of Indonesia.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. Submitted 30/04/2025, LSHTM Research Ethics Committee (Keppel Street, London, WC1E 7HT, United Kingdom; +44 20 7927 2221; ethics@lshtm.ac.uk), ref: 32017
2. Not yet submitted, Medical and Health Research Ethics Committee (Bulaksumur, Depok, Sleman Regency, Special Region of Yogyakarta, 55281, Indonesia; +62 8112666869; mhrec_fmugm@ugm.ac.id), ref: Reference number not provided
3. Not yet submitted, UNSW Human Research Ethics Committee (UNSW Sydney, Sydney, NSW 2052, Australia; +61 2 93851000; humanethics@unsw.edu.au), ref: Reference number not provided
4. Submitted 14/05/2025, Komisi etik bidang kesehatan BRIN (Ethical Committee of Health of BRIN) (Jl. MH. Thamrin No. 8 Gd. BJ Habibie Lt. 8,, Jakarta Pusat, 10340, Indonesia; +62 811-1933-3639; klirensetik@brin.go.id), ref: 14052025000001

Study design

Facility-based multi-centre two-arm parallel cluster randomized implementation trial

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Study setting(s)

Community

Study type(s)

Prevention, Screening, Treatment

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Improving syphilis screening and management in pregnant women

Interventions

The information from East Nusa Tenggara and Central Java will inform site selection and ensure balanced and buffered randomization of Puskesmas in a 1:1 ratio to either intervention or control (current practice) arms. The randomization will be conducted in STATA.

The intervention Puskesmas will receive targeted and enhanced support to promote the screening for and management of syphilis. The intervention has four components: i) Supply management system which will provide support to avoid delays in confirmatory testing and treatment initiation including optimisation of distribution and logistics, root cause analysis and implementation of standard operating procedures (SOPs) to strengthen inventory management systems. ii) Decision support tools including development and implementation of flow charts, SOPs and a supplementary syphilis birth plan (complete mother/baby pair record of syphilis management data) iii) Training of private and public midwives using a Training of trainers (ToT) programme that will be co-developed with the district health office and Puskesmas staff and implemented by the NGO partner to address hesitancy and lack of clarity about testing and treatment pathways for syphilis to iv) Education and awareness program which will include development of flyers, posters, infographics and animated videos that will be used to implement a facility-based awareness program to raise awareness of early screening and treatment for syphilis.

The total duration of the intervention will be 12 months. In order to collect birth outcomes, both intervention and control arms will be followed up for an additional 6 months after the intervention has stopped.

Intervention Type

Behavioural

Primary outcome measure

1. The proportion of women screened for syphilis during the first trimester is measured using secondary data reported in ANC registers and in the online surveillance systems at baseline, midline (6 months) and endline (12 months)
2. The proportion of women testing positive for syphilis who receive at least one dose of benzylpenicillin is measured using secondary data reported in ANC registers, in the online surveillance systems, and patient interviews, monthly including at endline (12 months)

Secondary outcome measures

1. The proportion of women with a positive syphilis test who are managed according to guidelines is measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).
2. The proportion of women testing positive for syphilis who complete treatment at least 30 days before delivery is measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).
3. The proportion of women testing positive with a birth plan at the time of delivery is measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).
4. Birth outcomes in women testing positive for syphilis, including spontaneous abortions, intrauterine fetal deaths, preterm birth or low birth weight, are measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).
5. The proportion of women tested for HIV in the first trimester is measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).

6. The proportion of women tested for HBV in the first trimester is measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).
7. The proportion of women tested for all three infections in the first trimester is measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).
8. The proportion of women tested for all three infections during pregnancy is measured using secondary data reported in ANC registers, and patient interviews at midpoint (6 months) and at endline (12 months).
9. The proportion of women testing positive for HIV who are started on ARV treatment within 2 weeks is measured using secondary data reported in ANC registers and patient interviews at midpoint (6 months) and at endline (12 months).
10. The total cost and cost-effectiveness of the intervention compared to standard care is measured using secondary data from project/facility/district financial accounts, patient diaries and time-in-motion studies at endline (12 months).
11. Uptake and acceptability of the multi-faceted intervention among key stakeholders is measured using stakeholder interviews at endline (12 months).

Overall study start date

01/08/2024

Completion date

30/09/2027

Eligibility

Key inclusion criteria

1. Facility eligibility: Eligible Puskesmas must:
 - 1.1. Serve a mean of at least 320 new pregnant women per year, with
 - 1.2. A burden of syphilis in pregnancy above the national average
2. Individual eligibility: All women attending their first ANC visit at participating Puskesmas or its network of community and private midwives, will be eligible to participate.

Participant type(s)

Health professional, Service user, Other

Age group

Mixed

Lower age limit

16 Years

Upper age limit

99 Years

Sex

Female

Target number of participants

20 Puskesmas will be allocated to each arm, which is a total of 40 Puskesmas. Baseline data will however be collected from 50, to allow for Puskesmas to drop out or to be excluded before arm allocation. The total number of pregnant women's records extracted will be approximately 12800 based on an annual ANC attendance of at least 320 women per year. For the context and process evaluation, the final sample sizes will be determined by data saturation, following initial sets of 5-6 interviews in each category of participants.

Key exclusion criteria

Puskesmas participating in any interventions to promote syphilis detection and management

Date of first enrolment

01/09/2025

Date of final enrolment

31/08/2027

Locations

Countries of recruitment

Indonesia

Study participating centre**Puskesmas in Central Java**

Indonesia

Central Java

Study participating centre**Puskesmas in East Nusa Tenggara**

Indonesia

East Nusa Tenggara

Sponsor information

Organisation

Universitas Gadjah Mada

Sponsor details

Center for Tropical Medicine

Gedung Penelitian dan Pengembangan FKMK UGM

Jl. Medika, Sendowo, Sinduadi, Kec. Mlati, Kab Sleman

Yogyakarta

Indonesia

55281

+62(274)588688
ari.probandari@staff.uns.ac.id

Sponsor type

University/education

Website

<https://ugm.ac.id>

ROR

<https://ror.org/03ke6d638>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

At the end of the study, we will provide formal feedback with recommendations for improvement of syphilis management for all health facilities, as well as to the Ministry of Health.

Intention to publish date**Individual participant data (IPD) sharing plan**

The project data will be deposited in the UK Data Archive and LSHTM Research Data Repository to make it accessible to other researchers in accordance with LSHTM Records Management Policy and MRC guidance. Sharing of the de-identified study data files will be permitted under strict data-sharing agreements and/or user registration. We will only share de-identified study

data files. As part of the registration/data-sharing agreement process, users must agree to conditions including: 1) restrictions against attempting to identify participants, 2) commitment to securing the data using appropriate technology, 3) destruction of data after analyses are completed, 4) reporting responsibilities, 5) restrictions on redistribution of data, and 6) proper acknowledgement of the data source.

IPD sharing plan summary

Stored in non-publicly available repository, Available on request